Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Covid19, SARS-CoV Infection, ARDS, ARDS, Human

In brief

Acute treatment of COVID-ARDS with direct topical lung instilled T3 therapy for patients on mechanical ventilation.

Key facts

Study ID

NCT04725110

Run by

University of Minnesota

People needed

0

Starts

2026-01-15

Expected to finish

2031-10-15

Last updated by the study team

2026-02-10

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of SARS-CoV-2 with first positive test within 14 days, and,
• Diagnosis of ARDS by the Berlin Criteria (2012):
• Onset: < 7 days
• Chest x-ray: Bilateral Patchy Opacities, Infiltrates
• Mechanical Vent Support: PEEP or CPAP Support >= 5 cm H2O
• Pulmonary Edema: Not fully explained by cardiogenic etiology
• Hypoxia: PaO2/FIO2 Ratio < 300, or O2Sat/FIO2 Ratio < 315

You may not qualify if…

• Pregnancy
• Inclusion Criteria:
• Diagnosis of SARS-CoV-2 with first positive test within 14 days, and,
• Diagnosis of ARDS by the Berlin Criteria (2012):
• Onset: < 7 days
• Chest x-ray: Bilateral Patchy Opacities, Infiltrates
• Mechanical Vent Support: PEEP or CPAP Support >= 5 cm H2O
• Pulmonary Edema: Not fully explained by cardiogenic etiology
• Hypoxia: PaO2/FIO2 Ratio < 300, or O2Sat/FIO2 Ratio < 315

Where it is running

• University of Minnesota — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.